相似文献
1
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Breast Cancer Res. 2009;11(6):111. doi: 10.1186/bcr2451. Epub 2009 Nov 26.
2
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Breast Cancer Res. 2009;11(6):R78. doi: 10.1186/bcr2445. Epub 2009 Nov 9.
3
The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Int J Biol Sci. 2006;2(4):179-85. doi: 10.7150/ijbs.2.179. Epub 2006 Jun 10.
4
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Ann Oncol. 2011 Jan;22 Suppl 1:i53-9. doi: 10.1093/annonc/mdq667.
5
[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84. doi: 10.5604/17322693.1000548.
6
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15.
7
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
Cancer Biol Ther. 2005 Sep;4(9):934-6. doi: 10.4161/cbt.4.9.2141. Epub 2005 Sep 1.
8
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
9
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
Mol Med. 2011;17(7-8):854-62. doi: 10.2119/molmed.2010.00240. Epub 2011 Mar 11.
10
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.
引用本文的文献
1
The expanding universe of PARP1-mediated molecular and therapeutic mechanisms.
Mol Cell. 2022 Jun 16;82(12):2315-2334. doi: 10.1016/j.molcel.2022.02.021. Epub 2022 Mar 9.
2
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.
Life Sci Alliance. 2021 Oct 5;4(12). doi: 10.26508/lsa.202101144. Print 2021 Dec.
3
The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling.
PLoS One. 2021 Feb 11;16(2):e0245876. doi: 10.1371/journal.pone.0245876. eCollection 2021.
4
The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.
5
A Natural Quinazoline Derivative from Marine Sponge Induces Apoptosis of Breast Cancer Cells via ROS Production and Intrinsic or Extrinsic Apoptosis Pathways.
Mar Drugs. 2019 Nov 23;17(12):658. doi: 10.3390/md17120658.
6
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.
Mol Cell. 2019 Sep 19;75(6):1270-1285.e14. doi: 10.1016/j.molcel.2019.06.020. Epub 2019 Jul 24.
7
Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Oncotarget. 2018 Jun 19;9(47):28456-28473. doi: 10.18632/oncotarget.25466.
8
Antiproliferative and Proapoptotic Activities of Marine Sponge Extract on Breast Carcinoma Cell Line (MCF-7).
Pharmacogn Mag. 2017 Jan;13(Suppl 1):S41-S47. doi: 10.4103/0973-1296.203983. Epub 2017 Apr 7.
9
Silencing of ZRF1 impedes survival of estrogen receptor positive MCF-7 cells and potentiates the effect of curcumin.
Tumour Biol. 2016 Sep;37(9):12535-12546. doi: 10.1007/s13277-016-5114-y. Epub 2016 Jun 27.
10
Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Int J Clin Exp Pathol. 2015 Jun 1;8(6):7059-71. eCollection 2015.
本文引用的文献
1
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Breast Cancer Res. 2009;11(6):R78. doi: 10.1186/bcr2445. Epub 2009 Nov 9.
2
PARP inhibitors blaze a trail in difficult-to-treat cancers.
Nat Biotechnol. 2009 Sep;27(9):784-6. doi: 10.1038/nbt0909-784.
3
PARP inhibitors: will the new class of drugs match the hype?
J Natl Cancer Inst. 2009 Sep 16;101(18):1230-2. doi: 10.1093/jnci/djp315. Epub 2009 Sep 8.
4
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
5
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.
6
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.
Curr Opin Cell Biol. 2008 Jun;20(3):294-302. doi: 10.1016/j.ceb.2008.03.006. Epub 2008 Apr 29.
7
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Mutat Res. 2007 Aug 15;632(1-2):20-8. doi: 10.1016/j.mrgentox.2007.04.011. Epub 2007 Apr 21.
8
DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation.
Mol Cell. 2007 Jan 26;25(2):297-308. doi: 10.1016/j.molcel.2006.12.012.
9
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Oncogene. 2007 May 31;26(26):3857-67. doi: 10.1038/sj.onc.1210156. Epub 2006 Dec 11.
10
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell. 2006 Dec;10(6):515-27. doi: 10.1016/j.ccr.2006.10.008.
Zotero 插件